Enzo Tedone obtained his Ph.D. from the University of Milan with focus on the discovery of new biomarkers of healthy aging. He was a post-doctoral fellow at UT Southwestern Medical Center in the lab of Jerry W. Shay, studying the relationship of telomere shortening and aging and new approaches for safely elongating shortened telomeres. He is a recipient of the 2019 Forbeck Scholar Award, as well as the author of eighteen scientific publications and one US Patent.

Mohammad E. Sayed is a Co-Founder and pioneering scientist at Telos. He holds a Ph.D. obtained from Dr. Shay's lab at UT Southwestern Medical Center, where he specialized in studying cancer as a disease of aging. Throughout his career, Dr. Sayed has dedicated himself to unraveling the underlying mechanisms driving both cancer and aging, with the ultimate goal of developing targeted therapies. His research has encompassed a diverse range of subjects, including protein engineering, alternative splicing (RNA biology), and adoptive cell and gene therapies, resulting in his extensive expertise in these areas. He is the author of seven scientific publications and one US Patent.

Jerry Shay is the Associate Director of the Harold Simmons NCI Designated Comprehensive Cancer Center, a Distinguished Chair in Geriatrics Research, and a consultant and scientific advisory board member for companies such as Procter Gamble, Corixa, BioWhitaker, Clontech, Rexahn, Sierra Science and Elizabeth Therapeutics. He co-founded Geron Corporation focused on telomerase therapeutics and is the Scientific Founder and member of the SAB for Barricade Therapeutics focused on developing a targeted therapy for colon cancer. Jerry is also the Scientific Founder and Chairman of the Scientific Advisory Board of THIO, part of Maia Biotechnology, an early-stage company developing targeted therapies with novel mechanisms of action. He received his BA from UT Austin and PhD from UC Boulder.